Updates are available Correction dated 2023-06-20
Click to view Correction: https://doi.org/10.1038/s41596-023-00858-z
-
Authors
Huang, Kuan-Ting
Poganik, Jesse R.
Parvez, Saba
Raja, Sruthi
Miller, Brian
Long, Marcus J. C.
Fetcho, Joseph R.
Aye, Yimon https://orcid.org/0000-0002-1256-4159
-
Funding
Funding for this research was provided by:
Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung
École Polytechnique Fédérale de Lausanne
NIH CBI training grant AHA predoctoral fellowship
HHMI International Fellow
- License Information
-
More Information
Article History
Received: 24 March 2017
Accepted: 5 December 2022
First Online: 5 April 2023
Change Date: 20 June 2023
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1038/s41596-023-00858-z
Competing interests
: REX technologies and small-molecule inhibitors discovered from applications of REX technologies, have been filed for patent applications. Y.A. and M.J.C.L. filed a patent application on the G-REX technology and Y.A. and M.J.C.L. filed a patent application on the Akt3-isoform-specific covalent inhibitor.
